Programmed Innate Leukocytes as Potent Therapeutic Agents to Treat Atherosclerosis and Stroke

This invention discloses a novel strategy to reprogram either allogenic or heterologous peripheral blood neutrophils and/or monocytes with a selective compound in vitro, into a homeostatic state that is conducive for healing of coronary heart disease and/or stroke.  Reprogrammed monocytes and/or neutrophils can be used through i.v. injection into human patients for therapeutic treatment. 

Patent Information:
For Information, Contact:
Elizabeth Garami
Associate Director
Virginia Tech Intellectual Properties, Inc.
Liwu Li
Shuo Geng
Yao Zhang